Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
Nature Medicine, Published online: 15 September 2026; doi:10.1038/s41591-026-04559-4 In a phase 1 trial evaluating GFH375, an oral, dual on–off binding KRAS G12D inhibitor, in patients with KRASG12D-mutated solid tumors, there was one…
Read the full story at Nature Medicine ↗
ImpactNotable 38/100
Why it mattersRule-based estimate: no strong signals; trust 10/10.
RegionsGlobal
Published4 d ago (Tue, 15 Sep 2026 00:00:00 GMT)
RetrievedWed, 16 Sep 2026 00:01:10 GMT via rdf
ClassifiedWed, 16 Sep 2026 03:31:10 GMT by heuristic
AuthorXinghao Ai